Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
  • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1034—Isolating an individual clone by screening libraries
  • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
  • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
  • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/90—Stable introduction of foreign DNA into chromosome
  • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
  • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2800/00—Nucleic acids vectors
  • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2810/00—Vectors comprising a targeting moiety
  • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention generally relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly interspaced Short Palindromic Repeats (CRISPR) and components thereof.
• sequence targeting such as genome perturbation or gene-editing
• CRISPR Clustered Regularly interspaced Short Palindromic Repeats
• the CRISPR/Cas or the CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA. molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases.
• An exemplary CRISPR complex comprises a CRISPR enzyme compfexed with a guide sequence hybridized to a target sequence within the target polynucleotide, wherein the CRISPR enzyme is a Cas ortholog, e.g.
• a Cas9 ortholog of a genus which includes but is not limited to Coiynebacter, Sutierella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.
• the guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
• the invention provides methods for using one or more elements of a CRISPR system.
• the CRISPR complex of the invention provides an effective means for modifying a target polynucleotide.
• the CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating, repressing, altering methylation, transferring specific moieties) a target polynucleotide in a multiplicity of cel l types.
• modifying e.g., deleting, inserting, translocating, inactivating, activating, repressing, altering methylation, transferring specific moieties
• the CRISPR complex of the invention has a broad spectmm of applications in, e.g., gene or genome editing, gene regulation, gene therapy, drug discovery, drug screening, disease diagnosis, and prognosis.
• the CRISPR complex comprises a Cas enzyme, preferably a Cas9 ortholog, of a genus which includes but is not limited to Coiynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.
• a Cas enzyme preferably a Cas9 ortholog
• aspects of the invention relate to CR ISPR. enzymes having optimized function.
• the CRISPR enzyme being a Cas enzyme
• preferred embodiments of the invention relate to Cas9 orthologs having improved target specificity in a CRISPR-Cas9 system. This may be accomplished by approaches that include but are not limited to designing and preparing guide RNAs having optimal activity, selecting Cas9 enzymes of a specific length, truncating the Cas9 enzyme making it smaller in length than the corresponding wild-type Cas9 enzyme by truncating the nucleic acid molecules coding therefor and generating chimeric Cas9 enzymes wherein different parts of the enzyme are swapped or exchanged between different orthologs to arrive at chimeric enzymes having tailored specificity.
• aspects of the invention also relate to methods of improving the target specificity of a Cas9 ortholog enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 ortholog enzyme having a smaller size or length than the corresponding wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is advanced as there is less coding sequence therefor in the delivery vector than for the corresponding wild-type Cas9 and/or generating chimeric Cas9 enzymes.
• a CRISPR enzyme e.g. a Cas9 en/.yrvic may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to or being operably linked to a functional domain.
• the mutations may be artificially introduced mutations and may include but are not limited to one or more mutations in a catalytic domain.
• Examples of catalytic domains with reference to a Cas9 enzyme may include but are not limited to RuvC I, RuvC II, RuvC III and HNH domains.
• suitable mutations are the catalytic residue(s) in the N-term RuvC I domain of Cas9 or the catalytic residue(s) in the internal HNH domain, in some embodiments, the Cas9 is (or is derived from) the Streptococcus pyogenes Cas9 (SpCas9). In such embodiments, preferred mutations are at any or al l of positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 or corresponding positions in other Cas9 ortliologs with reference to the position numbering of SpCas9 (which may be ascertained for instance by standard sequence comparison tools, e.g. C!ustalW or MegAlign by Lasergene 10 suite).
• any or all of the following mutations are preferred in SpCas9: DIOA, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged.
• the same mutations (or conservative substitutions of these mutations) at corresponding positions with reference to the position numbering of SpCas9 in other Cas9 orthologs are also preferred.
• Particularly preferred are D10 and H840 in SpCas9.
• residues corresponding to SpCas9 D10 and H840 are also preferred.
• mutated Cas 9 enzyme being fused to or operably linked to domains which include but are not limited to a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducible/contro!lable domain or a chemical Sy induci b 1 e/contro liable domain .
• a further aspect of the invention provides for chimeric Cas9 proteins and methods of generating chimeric Cas9 proteins.
• Chimeric Cas9 proteins are proteins that comprise fragments that originate from different Cas9 orthologs. For instance, the -terminal of a first Cas9 ortholog may be fused with the C-terminal of a second Cas9 ortholog to generate a resultant Cas9 chimeric protein.
• These chimeric Cas9 proteins may have a higher specificity or a higher efficiency than the original specificity or efficiency of either of the individual Cas9 enzymes from which the chimeric protein was generated.
• These chimeric proteins may also comprise one or more mutations or may be linked to one or more functional domains.
• aspects of the invention relate to a chimeric Cas enzyme wherein the enzyme comprises one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog.
• the one or more fragments of the first or second Cas ortholog are from the C- or N-terminal of the first or second Cas ortholog.
• the first or second Cas ortholog is selected from a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filif actor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, FlavUvola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter,
• the invention provides for methods to generate mutant components of the CRISP R complex comprising a Cas enzyme, e.g Cas9 ortholog.
• the mutant components may include but are not limited to mutant tracrRNA and tracr mate sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells.
• Use of the present composition or the enzyme in the preparation of a medicament for modification of a target sequence is also provided.
• the invention in yet a further aspect provides compositions and methods related to a non-naturally occurring or engineered composition comprising :
• a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence wherein the polynucleotide sequence comprises:
• a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences
• the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence
• the CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA
• the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence
• the CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA
• the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Fiaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.
• the i ve tion in yet a further aspect provides: (A) A non-naturally occurring or engmeered composition comprising a vector system comprising one or more vectors comprising; I. a first regulatory element operabiy linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II.
• chiRNA chimeric RNA
• a second regulatory element operabiy linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence- specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bactero
• a first regulatory element operabiy linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operabiy linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III.
• a third regulator ⁇ 7 element operabiy linked to a tracr sequence wherein components I, II and III are located on the same or different vectors of the system, wherein whe transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence- specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that, is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria,
• the CRISPR enzyme having a specific size is selected and has a length of at least 500 amino acids, at least 800-899 amino acids, at least. 900-999 amino acids, at least. 1000-1099 amino acids, at. least 1100-1 1 9 amino acids, at least. 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids;
• the CRISPR enzyme is tru cated in comparison to the correspo ding wild type CRISPR enzyme
• the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase directing cleavage of one strand at the location of the target sequence;
• the guide seque ce comprises at least 10, at least 15 or at least 20 nucleotides
• the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell
• the CRISPR enzyme comprises one or more mutations
• the CRISPR enzyme comprises a chimeric CRISPR enzyme
• the CRISPR enzyme is truncated in comparison to a wild type CRISPR enzyme or the CRISPR enzyme is comprised of at least 500 amino acids, at least 800- 899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at. least 1100- 1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400- .1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least. 2000 amino acids.
• the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.
• the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase directing cleavage of one strand at the location of the target sequence.
• the CRISPR enzyme is a eatalytieally null mutant that is a generic DNA binding protein.
• the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.
• the guide sequence comprises at least fifteen nucleotides, in some embodiments, the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic ceil. In some embodiments, the CRISPR enzyme comprises one or more mutations. In some embodiments, the CRISPR enzyme comprises a chimeric CRISPR enzyme. In some embodiments, the CRISPR enzyme has one or more other attributes herein discussed. In preferred embodiments the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.
• the CRISPR enzyme comprises one or more mutations.
• the one or more mutations may be in a particular domain of the enzyme.
• the one or more mutations may be in a catalytic domain.
• the catalytic domain is a RuvC L RuvC II, RuvC II I or HN domain.
• the one or more mutations is in a RuvCl or HNH domain of the CRISPR enzyme.
• the CRISPR enzyme is a Cas enzyme, e.g.
• the CRISPR enzyme has one or more mutations in a particular domain of the enzyme, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the enzyme further comprises a functional domain.
• the functional domain may include but is not limited to transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA. methyltransferase, a cryptochrome, a light mdueible/controilable domain or a chemically inducible/controIlabSe domain.
• the functional domain is the transcriptional activator domain VP64. In some embodiments, the functional domain is the transcriptional repressor domain KRAB. In some embodiments, the transcriptional repressor domain is SID, or concatemers of SID (i.e. SID4X). In some embodiments, an epigenetic modifying enzyme is provided, e.g a histone modifying protein or an epigenetic chromatin modifying protein. In some embodiments, an activator domain is provided, which may be the P65 activator domain.
• a further aspect of the invention comprehends methods of modifying two or more genomic loci of interest.
• two or more genomic loci are differentially modulated by utilizing one or more CRISPR enzymes, e.g. two or more Cas9 orthologs, each ortholog being operably linked to one or more functional domain.
• the invention provides for a method of modifying two or more genomic loci in a eukaryotic cell. Therefore, aspects of the in vention provide for a method of modulating the expression of two or more genomic loci of interest in an organism comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising
• a first regulator ⁇ ' element operably linked to a first CRJSPR-Cas system chimeric RNA (chiRNA) polynucleotide seque ce, wherein the first polynucleotide sequence comprises
• a second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence comprises
• a third regulatory element operably linked to an enzyme-coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain
• a fourth regulatory element operably linked to an enzyme-coding sequence encoding a second CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a second functional domain, wherein (i), (ii) and (iii) in J and II are arranged in a 5' to 3' orientation, wherein components I, II, III and IV are located on the same or different vectors of the system, wherein when transcribed, each tracr mate sequences hybridizes to its corresponding tracr sequence and the first and second guide sequences direct sequence-specific binding of the first and second CRJSPR complex to the first and second target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and wherein expression of the CRISPR enzyme provides manipulation of the target sequence, wherein the first and second CRISPR enzyme each comprise two or more mutations, wherein the first and second CRISPR enzyme
• the first functional domain is selected from the group consisting of a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome and a light inducible/controllable domain or a chemically inducible/controllabie domain.
• the second functional domain is selected from the group consisting of a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome and a light inducibie/contro!lable domain or a chemically inducible/controllable domain.
• the first or second CRISPR enzyme is a Sutterella wadsworthensis Cas9, a FiSifactor alocis Cas9, a Lactobacillus johnsonii Cas9, a Campylobacter lari Cas9, a Corynebacter diptheriae Cas9, a Parvibaculum lavamentivorans Cas9, a Mycoplasma gailisepticum Cas9, a Staphylococcus aureus subsubspecies Aureus Cas9, a Legionella pneumophila Paris Cas9, a Treponema denticola Cas9, a Staphylococcus pseudintermedius Cas9, a Neisseria cinerea Cas9.
• the CRISPR enzyme is a type I, II or I II CRISPR enzyme, preferably a type II CRISPR enzyme.
• This type II CRISPR enzyme may be any Cas enzyme.
• a Cas enzyme may be identified as Cas9 as this can refer to the genera! class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system.
• the Cas9 enzyme is from, or is derived from, SpCas9 or Staphylococcus aureus subsubspecies Aureus SaCas9,
• derived it is meant that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) i some way as described herein.
• this invention includes many more Cas9s from other species of microbes such as those belonging to the genus Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma or Campylobacter, such as SpCas9, SaCas9, StlCas9, St3Cas9 and so forth, wherein St is Streptococcus thermophilus.
• FIG. 1 Further aspects of the invention relate to improved cleavage specificity, optimized tracr sequence, optimized chimeric guide RNA, co-fold structure of tracrRNA and tracr mate sequence, stabilizing secondary structures of tracr RNA, tracrRNA with shortened region of base pairing, tracrRNA with fused RNA elements, simplified cloning and delivery, reduced toxicity and/or inducible systems.
• Another aspect of the invention relates to the stabilization of chimeric RNA, and/or guide sequence and or a portion thereof of CRISPR complexes wherein the CRISPR enzyme is a CRISPR ortholog, wherein the chimeric RNA, and/or guide sequence and or a portion thereof is stabilized by synthetic or chemically modified nucleotides (e.g. LNA/BNA; thiol-modification, 273' -OH crosslink modification), is modified to be degradatiou/rrydrolysis resistant and to which elements of structural stability have been added.
• synthetic or chemically modified nucleotides e.g. LNA/BNA; thiol-modification, 273' -OH crosslink modification
• the invention further comprehends in certain embodiments a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a noii-naturaily occurri g or engineered composition comprising a vector system comprising one or more vectors operably encoding a composition herein discussed for expression thereof.
• the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided.
• the CRJSPR enzyme for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can be delivered using adeno associated vims (AAV), lenti virus, adenovirus or other viral vector types, or combinations thereof.
• Cas9 and one or more guide RNAs can be packaged into one or more viral vectors.
• the viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while othertimes the viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods.
• Such delivery may be either via a single dose, or multiple doses.
• the actual dosage to be delivered herein may vary great!)? depending upon a variety of factors, such as the vector chosen, the target cell, organism, or tissue, the general condition of the subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transformation/modification sought, etc.
• Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable carrier (e.g., phosphate-buffered saline), a pharmaceutieally-aeceptable excipient, an adjuvant to enhance antigenicity, an immunostimulatory compound or molecule, and/or other compounds known in the art.
• a carrier water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.
• a pharmaceutically-acceptable carrier e.g., phosphate-buffered saline
• the adjuvant herein may contain a suspension of minerals (alum, aluminum hydroxide, aluminum phosphate) o which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in oil (MF-59, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (inhibits degradation of antigen and/or causes influx of macrophages).
• Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, and for example, immunostimulatory DNA or RNA molecules, such as CpG oligonucleotides.
• the dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoates, etc.
• auxiliary substances such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present.
• one or more other conventional pharmaceutical ingredients such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutable form.
• Suitable exemplary ingredients include microcrystaliine cellulose, carboxymethyleellulose sodium, polysorbate 80, phenylethyi alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof
• microcrystaliine cellulose carboxymethyleellulose sodium, polysorbate 80, phenylethyi alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof
• the delivery is via an adenovirus, which may be at a single booster dose containing at least 1 x 1Q J particles (also referred to as particle units, pu) of adenoviral vector.
• the dose preferably is at least about 1 x 10°
• particles for example, about 1 x 10 -1 x 10 " particles), more preferably at least about 1 x 10' particles, more preferably at least about 1 10" particles (e.g., about 1 x 10 -1 x 10 particles or
• the dose comprises no more than about 1 x 10 14 particles, preferably no more than about 1 x 10°
• particles even more preferably no more than about 1 x 10 ' particles, even more preferably no more than about 1 x 10 11 particles, and most preferably no more than about I x 10 l0 particles (e.g., no more than about 1 x 10 y articles).
• the dose may contain a single dose of adenoviral vector with, for example, about 1 x 10 6 particle units (pu), about 2 x 10° pu, about 4 x 10 6 pu, about 1 x 1() 7 pu, about 2 x 10 7 pu, about 4 x 10' pu, about 1 x 10 s pu, about 2 x 10 s pu, about 4 x 10 8 pu, about 1 x 1Q 9 pu, about 2 x 10 9 pu, about 4 x 10 9 pu, about 1 x I0 1 " pu, about 2 x 10 ⁇ pu, about 4 x 10 1 pu, about I x l O' 1 pu, about 2 x 10 l 3 pu, about 4 x 10 3 3 pu, about 1 x I0 1" pu, about 2 x 10° pu, or about 4 x 10 12 pu of adenoviral vector.
• adenoviral vector with, for example, about 1 x 10 6 particle units (pu), about 2 x 10° pu, about 4 x 10 6 pu,
• the adenoviral vectors in U.S. Patent No. 8,454,972 B2 to Nabel, et. ai, granted on June 4, 2013; incorporated by reference herein, and the dosages at col 29, lines 36-58 thereof.
• the adenovirus is delivered via multiple doses.
• the delivery is via an AAV.
• a therapeutically effective dosage for in vivo deliver)' of the AAV to a human is believed to be in the range of from about 20 to about 50 ml of saline solution containing from about 1 x 10 to about 1 x 10 functional AAV/ml solution. The dosage may be adjusted to balance the therapeutic benefit agamst any side effects.
• the AAV dose is generally in the range of concentrations of from about 1 x 10 5 to 1 x 10 5U genomes AAV, from about 1 x 10 8 to 1 x 10 20 genomes AAV, from about 1 x 10 1 " to about 1 x 10 lu genomes, or about 1 x 10 l !
• a human dosage may be about 1 10 13 genomes AAV. Such concentrations may be delivered in from about 0.001 mi to about 100 ml, about 0.05 to about 50 mi, or about 10 to about 25 ml of a carrier solution. Other effective dosages can be readily established by one of ordinary skil l in the art through routine trials establishing dose response curves. See, for example, U.S. Patent No. 8,404,658 B2 to Hajjar, et al., granted on March 26, 2013, at col. 27, lines 45-60.
• the delivery is via a plasmid.
• the dosage should be a sufficient amount of plasmid to elicit a response.
• suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about 1 ⁇ g to about 10 ⁇ ig.
• the doses herein are based on an average 70 kg individual.
• the frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), or scientist skilled in the art.
• the viral vectors can be injected into the tissue of interest.
• the expression of Cas9 can be driven by a cell-type specific promoter.
• liver- specific expression might use the Albumin promoter and neuron-specific expression might use the Synapsin I promoter.
• RNA delivery The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can also be delivered in the form of RNA.
• Cas9 niRNA can be generated using in vitro transcription.
• Cas9 mRNA can be synthesized using a PGR cassette containing the following elements: T7 promoter-kozak sequence (GCCACC)-Cas9-3 ' UTR from beta globin-polyA tail (a string of 120 or more adenines).
• the cassette can be used for transcription by T7 polymerase.
• Guide RNAs can also be transcribed using in vitro transcription from a cassette containing T7_promoter-GG-guide RNA sequence.
• the CRISPR enzyme and/or guide RNA can be modified using pseudo-U or 5-Methyl-C.
• CRISPR enzyme mRNA and guide RNA may be delivered simultaneously using nanoparticles or lipid envelopes.
• CRISPR enzyme mRNA and guideRNA might also be delivered separately, CRISPR enzyme mRNA can be delivered prior to the guide RNA to give time for CRISPR enzyme to be expressed.
• CRISPR enzyme mRNA might be administered 1-12 hours (preferably around 2-6 hours) prior to the administration of guideRNA.
• CRISPR. enzyme mRNA and guide RNA. can be administered together.
• a second booster dose of guide RNA can be administered 1 -12 hours (preferably around .2-6 hours) after the initial administration of CRISPR enzyme mRNA + guideRNA.
• CRISPR enzyme mRNA and/or guide RNA might be useful to achieve the most efficient, levels of genome modification.
• CRISPR enzyme mRNA. and guide RNA delivered For minimization of toxicity and off-target effects, it will be important to control the concentration of CRISPR enzyme mRNA. and guide RNA delivered.
• Optimal concentrations of CRISPR enzyme rnRNA and guide RNA can be determined by testing different concentrations in a cellular or animal model and using deep sequencing to analyze the extent of modification at potential off-target genomic loci. For example, for the guide sequence targeting 5'- GAGTCCGAGCAGAAGAAGAA-3' in the EMX1 gene of the human genome, deep sequencing can be used to assess the level of modification at the following two off -target loci, 1 : 5'-GAGTCCTAGCAGGAGAAGAA-3 ' and 2: 5 '-GAGTCTAAGCAGAAGAAGAA-3 ' . The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification should be chosen for in vivo delivery.
• CRISPR enzyme nickase mRNA for example S, pyogenes Cas9 with the D10A mutation
• CRISPR enzyme nickase mRNA can be deli vered with a pair of guide RNAs targeting a site of interest.
• the two guide RN As need to be spaced as follows. Guide seque ces in red (single underline) and blue (double underline) respectively (these examples are based on the PAM requirement for Streptococcus pyogenes Cas9).
• the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs.
• the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs or 1-34 base pairs.
• the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of other strand near the second target sequence results in a blunt cut or a 3' overhang.
• the 3' overhang is at most 150, 100 or 25 base pairs or at least 15, 10 or 1 base pairs. In preferred embodiments the 3' overhang is 1- 100 base pairs.
• aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased.
• the gene product is a protein.
• Additional delivery options for the brain include encapsulation of CRISPR enzyme and guide RNA in the form of either DNA or RNA into liposomes and conjugating to molecular Trojan horses for trans-blood brain barrier (BBB) delivery.
• BBB trans-blood brain barrier
• Molecular Trojan horses have been shown to be effective for delivery of B-gal expression vectors into the brain of non-human primates.
• the same approach can be used to delivery vectors containing CRISPR enzyme and guide RNA.
• Xia CF and Boado RJ, Pardridge WM Antibody-mediated targeting of siRNA via the human insulin receptor using avidm-biotm technology. Mol Pharm. 2009 May ⁇ Jun;6(3):747 ⁇ 5 I .
• siRNA short interfering RNA
• mAb monoclonal antibody
• avidm-biotm avidm-biotm
• the HlRMAb enables the liposome carrying the exogenous gene to undergo transcytosis across the blood -brain barrier and endocytosis across the ne uronal plasma membrane following intravenous injection.
• the level of luciferase gene expression in the brain was 50-fold higher in the rhesus monkey as compared to the rat.
• Widespread neuronal expression of the bcta- galaciosidase gene in primate brain was demonstrated by both histochemistry and confocal microscopy. The authors indicate that this approach makes feasible reversible adult transgenics in 24 hours. Accordingly, the use of inrmunoliposome is preferred. These may be used in conjuction with antibodies to target specific tissues or cell surface proteins.
• RNA delivery or RNA are also preferred, such as via nanoparticles (Clio, S., Goldberg, M., Son, S., Xu, Q., Yang, F., ei, Y., Bogatyrev, S., Larsger, R, and Anderson, D., Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Advanced Functional Materials, 19: 3112-31 18, 2010) or exosomes (Schroeder, A., Levins, C, Cortez, C, Langer, R., and Anderson, D., Lipid-based nanotherapeutics for siRNA delivery, Journal of Internal Medicine, 267: 9-21, 2010, PMID: 20059641).
• exozomes have been shown to be particularly useful in delivery siRNA, a system with some parallels to the CRISPR system.
• El-Andaloussi S, et ai (“Exosome-mediated delivery of siRNA in vitro and in vivo.” Nat Protoc. 2012 Dec;7(12):2112-26. doi: 10.1038/nprot.2012.131 . Epub 2012 Nov 15.) describe how exosomes are promising tools for ding delivery across different biological barriers and can be harnessed for delivery of siRNA in vitro and in vivo.
• Their approach is to generate targeted exosomes through transtection of an expression vector, comprising an exosomai protein fused with a peptide ligand. The exosomes are then purified and characterized from transfected ceil supernatant, then siRNA is loaded into the exosomes.
• One aspect of manipulation of a target sequence also refers to the epigenetic manipulation of a target sequence. This may be of the chromatin state of a target sequence, such as by modification of the methylation state of the target sequence (i.e. addition or removal of methylation or methylation patterns or CpG islands), hi stone modification, increasing or reducing accessibility to the target seque ce, or by promoting or reducing 3D folding.
• a vector may mean not only a viral or yeast system (for instance, where the nucleic acids of interest may be operabiy linked to and under the control of (in terms of expression, such as to ultimately provide a processed RNA) a promoter, but also direct deliver ⁇ .' of nucleic acids into a host cell.
• the invention also comprehends, in certain embodiments, a method of treating or inhibiting a condition caused by a detect in a target sequence in a genomic locus of interest in a subject or a non-human subject in need thereof comprising modifying the subject or a non- human subject by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non -naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising operabiy encoding a composition herein discussed for expression thereof * wherein the target sequence is manipulated by the composition when expressed.
• the methods can include inducing expression, which can be inducing expression of the CRISPR enzyme and/or inducing expression of the guide, tracr or tracr mate sequences.
• the organism or subject is a eukaryote or a non-human eukaryote.
• the organism or subject is a plant.
• the organism or subject is a mammal or a non-human mammal.
• the organism or subject is algae.
• the vector may be a viral vector and this is advantageously an AAV
• viral vectors as herein discussed can be employed.
• baculoviruses may be used for expression in insect cells. These insect cells may, in turn be useful for producing large quantities of further vectors, such as AAV vectors adapted for deliver ⁇ ' of the present invention.
• a method of delivering the present CRISPR enzyme comprising delivering to a cell mRNA encoding the CRISPR enzyme, it wil l be appreciated that the CRISPR enzyme is truncated, is of a specific size as decribed herein, is a nuclease or iiickase or generic DNA binding protein, is codon-optimized, comprises one or more mutations, and/or comprises a chimeric CRISPR enzyme, or the other options as herein discussed.
• AAV viral vectors are preferred.
• a method of preparing an AAV viral vector comprising transfecting plasmid(s) containing or consisting essentially of nucleic acid molecule(s) coding for the AAV into AAV-iiifeeted cells, and supplying AAV rep and/or cap obligatory for replication and packaging of the AAV.
• the CRISPR enzyme is truncated, comprised of less than one thousand amino acids or less than four thousand amino acids, is a nuclease or nickase, is codon- optimized comprises one or more mutations, and/or comprises a chimeric CRISPR enzyme, as herein discussed.
• the AAV rep and/or cap obligatory for replication and packaging of the AAV are supplied by transfecting the cells with helper plasmid(s) or helper virus(es).
• the helper virus is a poxvirus, adenovirus, herpesvirus or bacuiovirus.
• the poxvirus is a vaccinia virus.
• the cells are mammalian ceils. And in some embodiments the cells are insect cells and the helper virus is bacuiovirus.
• the invention further comprehends in certain embodiments a modified CRISPR enzyme. Differences from the wild type CRISPR enzyme can comprise: the modified CRISPR enzyme is truncated in comparison to a wild type CRISPR enzyme, or the CRISPR enzyme is of a specific size, e.g.
• the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase directing cleavage of one strand at the location of the target sequence, or the CRISPR enzyme is a catalytic null mutant that functions as a DNA binding protein; and/or the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell, and/or the CRISPR enzyme comprises one or more mutations, and/or the CRISPR enzyme comprises a chimeric CRISPR enzyme and/or the CRISPR enzyme
• the CR ISPR enzyme comprises one or more mutations in catalytic residues such as spCa9 D10A, E762A, H840A., N854A, 863.A or D986A or those corresponding to them in other Cas enzymes (as described herein) with reference to the positio numbering of SpCas9, and/or has one or more mutations is in a uvC I, RuvC ⁇ , RuvC I II HNH or other domain described herein of the CRISPR enzyme and/or the CRISPR enzyme has one or more mutations in a catalytic domain, wherein when transcribed, a tracr mate sequence hybridizes to a tracr sequence and a guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence, and wherein the enzyme further comprises a functional domain.
• catalytic residues such as spCa9 D10A, E762A, H840A., N854A, 863
• the functional domain may include but is not limited to transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA meihyltransferase, a eryptochrome, a light mducible/controllahle domain or a chemically inducible/controllable domain.
• the CRISPR enzyme in certain embodiments can have the functional domain be a transcriptional activator domain, e.g., VP64.
• a transcription repressor domains is KRAB.
• a transcription repressor domain is SID, or concatemers of SID (i.e. SID4X).
• an epigenetic modifying enzyme is provided.
• the CRSIPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.
• aspects of the invention also comprehend identifying novel orthologs of CRISPR enzymes.
• Methods of identifying novel orthologs of CRISPR enzymes may involve identifying tracr sequences in genomes of interest. Identification of tracr sequences may relate to the following steps: Search for the direct repeats or tracr mate sequences in a database to identify a CRISPR region comprising a CRISPR enzyme, e.g. Figure 18. Search for homologous sequences in the CRISPR region flanking the CRISPR enzyme in both the sense and antisense directions. Look for transcriptional terminators and secondary structures.
• the invention comprehends in certain embodiments use of a composition as described herein or a CRISPR enzyme in medicine.
• the invention further comprehends in certain embodiments a composition or CRISPR enzyme of the invention used in a method of the invention.
• the invention also comprehends, in certain embodiments, use of a composition or a CRISPR enzyme of the invention in, preferably ex vivo, gene or genome editing or, preferably an ex vivo, gene or genome editing method.
• the Invention accordingly also comprehends in certain embodiments use of a composition according or a CRISPR enzyme of the invention in the manufacture of a medicament for ex vivo gene or genome editin g or for use in a method as herein discussed.
• the invention in certain embodiments comprehends a composition or a CR1SPR enzyme of the invention, wherein the target sequence is flanked or followed, at its 3' end, by a PAM suitable for the CRISPR enzyme, typically a Cas and in particular a Cas9.
• a PAM suitable for the CRISPR enzyme typically a Cas and in particular a Cas9.
• This PAM sequence is specific for eac Cas9 but may be readily determined by methods described herein.
• a suitable PAM is 5'-NRG or S'-NNGRR for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively. It will be appreciated that reference made herein to Staphylococcus aureus preferably includes Staphylococcus aureus subspecies Aureus.
• Figure I shows a schematic of RNA-guided Cas9 nuclease.
• the Cas9 nuclease from Streptococcus pyogenes is targeted to genomic DNA by a synthetic guide RNA (sgR A) consisting of a 20-nt guide sequence and a scaffold.
• the guide sequence base-pairs with the DNA target, directly upstream of a requisite 5'-NGG protospacer adjacent motif (PAM), and Cas9 mediates a double-stranded break (DSB) ⁇ 3 bp upstream of the PAM (indicated by triangle).
• PAM protospacer adjacent motif
• Figure 2A-F shows an exemplary CRISPR system and a possible mechanism of action (A), an example adaptation for expression in eukaryotic cells, and results of tests assessing nuclear localization and CRISPR activity (B-F).
• Figure 3 shows a schematic representation of AAV in vivo delivery plasmids utilizing inverted terminal repeats (ITRs) sequences and guide chimeric RNAs to preferably aid delivery by AAV or AAV-associated systems.
• ITRs inverted terminal repeats
• Figure 4A-D shows a circular depiction of the phyiogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (-1100 amino acids).
• Figure 5 A-F shows a liner depiction of the phyiogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (- 1400 amino acids) and two of small Cas9s ( ⁇ 1100 amino acids),
• Figure 6 shows a graph representing the length distribution of Cas9 orthologs.
• Figure 7 shows a representation of the sequence logos of the PAMs of the Cas9 orthologs as reverse complements.
• Figure 8 A-J shows 18 chimeric RNA structures that preserved the sequence and secondary structures of the tracr mate:tracr sequence duplex while shortening the region of base- pairing and fusing the two RNA elements through an artificial loop.
• Figure 9 A-O shows a lis! of the human codon optimized Cas9 sequences to pair with the chimeric guide RNAs provided in Figures 8 A-j.
• Figure 10 A ⁇ M shows sequences where the mutation points are located within the SpCas9 gene.
• Figure 11 shows Type II CRISPR loci in different organisms
• Figure 12 shows guide UNA sequences corresponding to CRJSPR loci in different organisms.
• Figure 13 A ⁇ II shows a table listing Cas9 orthologs and their corresponding PAM sequences.
• Figure 14 shows that the PAM for Staphylococcus aureus subspecies Aureus Cas9 is NNGRR.
• Figure 15A-D shows single and multiple vector designs for SaCas9.
• Figrue 16 shows a vector design and gel images for Cas9 orthologs and respective sgRNAs being used to cleave two candidate targets present in a pUC19-based library.
• Figure 17 shows in vitro cleavage by SpCas9, St3Cas9, Sp St3 chimera and S ⁇ 3 Sp chimera.
• the PAMs for St3Cas9 and St3_Sp chimeric Cas9 are NGG.
• Figure 18 shows an image of the CRISPRs web server.
• Figure 19 A-L shows a multiple sequence alignment for 12 Cas9 orthologs. Two catalytic residues are highlighted. The first residue highlighted is the catalytic Asp residue in the RuvCl domain, and the second residue highlighted is the catalytic His residue in the HNH domain. Mutation of one or the other residue into Ala can convert Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically null mutant - useful for generic DNA binding.
• Figure 20 shows a western blot showing that Cas9 orthologs are expressed in HEK 293FT cells; DNA plasmids encoding Cas9 orthologs are transfected into HEK 293 FT cells and ceil lysates are harvested for Western blot. No DNA is transfected for Cas9 ortholog #8.
• Figure 21 shows in vitro cleavage of candidate targets on pUC19 plasmid by 10 Cas9 orthologs. Consensus PAMs are predicted by sequence logos ( Figure 7), based on which candidate targets on pUC19 are chosen. 7 of 9 new Cas9 orthologs tested have successfully cleaved at least one pUC19 target. SpCas9 can also cleave NGA in vitro.
• Figure 22 shows a Representative Surveyor Gel showing genomic cleavage by SaCas9.
• Figure 23 shows Genome Cleavage Efficiency of PAM Sequences (All targets),
• Figure 24 shows Genome Cleavage Efficiency of PAM Sequences (Cleaved targets)
• Figure 25 shows Genome Cleavage Efficiency of PAM Sequences (All targets, discard low-efficiency and orphan targets).
• Figiire 26 shows Genome Cleavage Efficiency of PAM Sequences (Cleaved targets, discard low-efficiency and orphan targets).
• Figure 27 shows a Sequence Logo for Working Cleaved Spacers & PAMs ( New endogenous genome test showing that T is not required).
• the invention relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to the CRISPR-Cas system and components thereof.
• the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.
• the invention uses nucleic acids to bind target DNA sequences. This is advantageous as nucleic acids are much easier and cheaper to produce than, for example, peptides, and the specificity can be varied according to the length of the stretch where homology is sought. Complex 3-D positioning of multiple fingers, for example is not required.
• polynucleotide refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown.
• polynucleotides coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger NA (rrsRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
• loci locus
• loci defined from linkage analysis, exons, introns, messenger NA (rrsRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleot
• a polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
• the sequence of nucleotides may be interrupted by iion-nucleotide components.
• a polynucleotide may be further modified after polymerization, such as by conjugation with, a labeling component.
• chimeric RNA refers to the polynucleotide sequence comprising the guide sequence, the tracr sequence and the tracr mate sequence.
• guide sequence refers to the about 20bp sequence within the guide RNA that specifies the target site and may be used interchangeably with the terms “guide” or “spacer”.
• tracr mate sequence may also be used interchangeably with the term “direct repeat(s)”.
• wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
• nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which the)' are naturally associated in nature and as fou d in nature.
• Complementarity refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non- traditional types.
• a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and .100%) complementary).
• Perfectly complementary means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.
• Substantially complementary refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under strin gen t condi tion s .
• stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non -target sequences.
• Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. No -limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology- Hybridization With Nucleic Acid Probes Part I, Second Chapter “Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y.
• complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridising to the reference sequence under highly stringent conditions.
• relatively low-stringency hybridization conditions are selected: about 20 to 25° C lower than the thermal melting point (Tm ).
• Tm is the temperature at which 50% of specific target sequence hybridizes to a perfectly complementary probe in solution at a defined ionic strength and pH.
• highly stringent washing conditions are selected to be about 5 to 15° C lower than the Tm .
• moderately-stringent washing conditions are selected to be about 15 to 30° C. lower than the Tm .
• Highly permissive (very low stringency) washing conditions may be as low as 50° C below the Tm , allowing a high level of mis-matching between hybridized sequences.
• Other physical and chemical parameters in the hybridization and wash stages can also be altered to affect the outcome of a detectable hybridization signal from a specific level of homology between target and probe sequences.
• Preferred highly stringent conditions comprise incubation in 50% formamide, 5 X SSC, and 1% SDS at 42° C, or incubation in 5xSSC and 1% SDS at 65° C, with wash in 0.2 SSC and 0.1% SDS at 65° C.
• Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogsteiii binding, or in any other sequence specific manner.
• the comple may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self- hybridizing strand, or any combination of these.
• a hybridization reaction may constitute a step in a more extensive process, such as the initiation of PGR, or the cleavage of a polynucleotide by an enzyme.
• a sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence.
• genomic locus or ''locus (plural loci) is the specific location of a gene or DNA sequence on a chromosome.
• a “gene” refers to stretches of DNA or RNA that encode a polypeptide or an RNA chain that has functional role to play in an organism and hence is the molecular unit of heredity in living organisms.
• genes include regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences.
• a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
• expression of a genomic locus or “gene expression” is the process by which information from a gene is used in the synthesis of a functional gene product.
• the products of gene expression are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is functional RNA.
• the process of gene expression is used by all known life - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products to survive.
• expression of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context.
• expression also refers to the process by which a poly ucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
• Transcripts and encoded polypeptides may be collectively referred to as "gene product.” If the polynucleotide is derived from genomic DMA, expression may include splicing of the mRNA. in a eukaryotic cell.
• polypeptide refers to polymers of amino acids of any length.
• the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids.
• the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
• amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomirneti.es.
• domain refers to a part of a protein sequence that may exist and function independently of the rest of the protein chain.
• sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. Sequence homologies may be generated by any of a number of computer programs known in the art, for example BLAST or FASTA, etc. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et ai., 1984, Nucleic Acids Research 12:387).
• Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et aL 1999 ibid - Chapter 18), FASTA (Atschul et ai., 1990, J. Mol. Biol., 403-410) and the GENEWO S suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program ,
• % homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues. [00117] Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion may cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed.
• sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without unduly penalizing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment to try to maximize local homology or identity.
• BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program, A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2): 247-50; FEMS Microbiol Lett. 1999 177(1): 187-8 and the website of the National Center for Biotechnology information at the website of the National Institutes for Health).
• the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pair-wise comparison based on chemical similarity or evolutionary distance.
• An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
• GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table, if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
• percentage homologies may be calculated using the multiple alignment feature in D ASISTM (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).
• % homology preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.
• sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
• Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups.
• Amino acids may be grouped together based on the properties of their side chains alone. However, it is more useful to include mutation data as well.
• the sets of amino acids thus derived are likely to be conserved for structural reasons. These sets may be described in the form of a Venn diagram (Livingstone CD. and Barton G.J.
• Embodiments of the invention include sequences (both polynucleotide or polypeptide) which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc.
• Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter refen'ed to as B), norleueirse ornithine (hereinafter referred to as O), pyridyialanine, thienylalanine, naphthylalanine and phenyiglyclne.
• Z ornithine
• B diaminobutyric acid ornithine
• O norleueirse ornithine
• pyridyialanine thienylalanine
• naphthylalanine phenyiglyclne
• Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ -alanine residues.
• alkyl groups such as methyl, ethyl or propyl groups
• amino acid spacers such as glycine or ⁇ -alanine residues.
• a further form of variation which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art.
• the peptoid form is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue's nitrogen atom rather tha the a-carbon.
• the invention provides for vectors that are used in the engineering and optimization of CRISPR-Cas systems.
• a "vector” is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. Generally, a vector is capable of replication when associated with the proper control elements. In general, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
• Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
• plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
• viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g.
• Viral vectors also include polynucleotides carried by a virus for transfeetion into a host cel l.
• Certain vectors are capable of autonomous replication in a host cel l into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
• Other vectors e.g., non-episomal mammalian vectors
• vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as ''expression vectors.”
• Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. Further discussion of vectors is provided herein.
• Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cel ls to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
• "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cel l when the vector is introduced into the host cel l).
• aspects and embodiments of the invention relate to bicistronic vectors for chimeric RNA and Cas9 or a Cas9 ortiiolog.
• the Cas9 is driven by the CBh promoter.
• the chimeric R NA. is driven by a U6 promoter.
• the CBh and U6 are used together in the sense that the Cas9 is driven by the CBh promoter and the chimeric RNA is driven by a U6 promoter.
• the chimeric guide RNA consists of a 20bp guide sequence (Ns) joined to the tracr sequence (running from the first "U" of the lower strand to the end of the transcript), which is truncated at various positions as indicated.
• the guide and tracr sequences are preferably separated by the tracr-mate sequence.
• a preferred example of a tracr-mate sequence is GUUUUAGAGCUA. This is preferably followed by a loop sequence.
• the loop is preferably GAAA, but it is not limited to this sequence or indeed to being only 4bp in length.
• preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA.
• chimeric RNA may also be called single guide, or synthetic guide RNA (sgRNA).
• sgRNA synthetic guide RNA
• regulatory element is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences).
• promoters e.g. promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences).
• IRES internal ribosomal entry sites
• regulatory elements e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences.
• Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
• a tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
• a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1 , 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g.
• pol III promoters include, but are not limited to, U6 and H I promoters.
• pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et ai, Ceil, 41 :521 -530 (1985)], the SV40 promoter, the dihydrofoiate reductase promoter, the ⁇ -aetin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF l a promoter.
• RSV Rous sarcoma virus
• CMV cytomegalovirus
• enhancer elements such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin (Proc. Natl. Acad . Sci. USA.., Vol. 78(3), p. 1527-31 , 1981 ). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc.
• a vector can be introduced into host eel Is to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
• CRISPR clustered regularly interspersed short palindromic repeats
• Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells.
• CRISPR transcripts e.g. nucleic acid transcripts, proteins, or enzymes
• CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).
• the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
• Vectors may be introduced and propagated in a prokaryote or prokaryotic cell.
• a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryottc cell (e.g. amplifying a plasmid as part of a viral vector packaging system).
• a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism.
• Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein.
• Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
• a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombi ant protein to enable separation of the recombina t protein from the fusio moiety subsequent to purification of the fusion protein.
• Such enzymes, and their cognate recognition sequences, i clude Factor Xa, thrombin and eiiterokinase.
• Example fusio expression vectors include pGEX (Pharmacia Biotech Ine; Smith and Johnson, 1988.
• GST glutathione S-transferase
• Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et a!., (1988) Gene 69:301 -315) and pET l i d (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
• a vector is a yeast expression vector.
• yeast expression vectors for expression in yeast Saccharomyces cerevisae include pYepSecl (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kuijan and Herskowitz, 1982. Ceil 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 1 13-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (inVitrogen Corp, San Diego, Calif.),
• a vector drives protein expression in insect cells using baculovirus expression vectors.
• Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).
• a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987.
• the expression vector's control functions are typically provided by one or more regulatory elements.
• promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art.
• suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd edminister Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
• the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
• tissue-specific regulatory elements are known in the art.
• suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1 : 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J.
• a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CRISPR system.
• CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
• SPIDRs Sacer Interspersed Direct Repeats
• SSRs interspersed short sequence repeats
• the CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (S SRs) (Janssen et al., OMICS J. Integ. Biol, 6:23-33 [2002]; and Mojica et al, Mol. MicrobioL, 36:244-246 [2000]).
• S SRs short regularly spaced repeats
• the repeats are short elements that occur in clusters thai are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et aL, [2000], supra).
• CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol.
• CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (tran -activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system h or other sequences and transcripts from a CRISPR locus.
• a tracr tran -activating CRISPR
• tracr-mate sequence encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system
• guide sequence also referred to as a "spacer” in the context of an endogenous CRIS
• one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR. system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
• target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex.
• a target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
• a target sequence is located in the nucleus or cytoplasm of a cell.
• the CRISPR system is a type II CRISPR system and the Cas enzyme is Cas9, which catalyzes DNA cleavage.
• the Cas enzyme is Cas9, which catalyzes DNA cleavage.
• Enzymatic action by Cas9 derived from Streptococcus pyogenes or any closely related Cas9 generates double stranded breaks at target site sequences which hybridize to 20 nucleotides of the guide sequence and that have a protospacer- adjacent motif (PAM) sequence NGG /NRG (for example, as discussed elsewhere, a suitable PAM is 5 -NRG or 5 -NNGRR for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively) following the 20 nucleotides of the target sequence.
• PAM protospacer- adjacent motif
• CRISPR activity through Cas9 for site-specific DNA recognition and cleavage is defined by the guide sequence, the tracr sequence that hybridizes in part to the guide sequence and the PAM sequence. More aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA-guided defense in bacteria and archae, Mole Cell 2010, January 15; 37(1): 7.
• the type II CRISPR locus from Streptooccus pyogenes SF370 contains a cluster of four genes Cas9, Casl, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers, about 30bp each).
• DSB targeted DNA double- strand break
• tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences.
• the mature crRNArtracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA.
• Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer ( Figure 2A).
• Figure 2B demonstrates the nuclear localization of the codon optimized Cas9.
• the RNA polymerase Ill-based U6 promoter was selected to drive the expression of tracrRN A ( Figure 2C).
• a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr-mate sequences"; Figure 2C).
• the initial spacer was designed to target a 33-base-pair (bp) target site (30-bp protospacer plus a 3 -bp CRISPR motif (PAM ) sequence satisfying the NGG recognition motif of Cas9) in the human EMX1 locus ( Figure 2C), a key gene in the development of the cerebral cortex.
• bp 33-base-pair
• PAM 3 -bp CRISPR motif
• Figure 16 shows Cas9 orthologs and respective sgRNAs are used to cleave two candidate targets present in a pUC19-bascd library.
• Target 1 is followed by a randomized PAM containing 7 degenerate bases (5 ! -NNNNNNN ⁇ 3 ! ), and target ⁇ , which contains the same target sequence as target 1, is followed by a fixed PAM (5'-TGGAGAAT-3').
• the sgRNA of each Cas9 ortholog contains the guide sequence against target 1 or target ⁇ .
• Gel images show successful cleavage by 20 Cas9 orthologs, indicating that these sgRNA designs are functional with their respective Cas9 enzymes.
• direct repeats or tracr mate sequences are either downloaded from the CRISPRs database or identified in silico by searching for repetitive motifs that are 1. found in a 2kb window of genomic sequence flanking the type II CRISPR locus, 2. span from 20 to 50 bp, and 3. interspaced by 20 to 50 bp.
• 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3.
• all 3 criteria may be used.
• candidate tracrRNA are subsequently predicted by 1. sequence homology to direct repeats (motif search in Geiieious with up to 18 -bp mismatches), 2. presence of a predicted Rho-independent transcriptional terminator in direction of transcription, and 3. stable hairpin secondary structure between tracrRNA and direct repeat.
• 2 of these criteria may be used, for instance I and 2, 2 and 3, or 1 and 3.
• all 3 criteria may be used.
• chimeric synthetic guide RNAs (sgRNAs) designs incorporate at least 8 bp of duplex structure between the direct repeat and traerRJMA.
• Optimal Cas9 activity may depend on the availability of free Mg2+ at levels higher than that present in the mammalian nucleus (see e.g. Jinek et ah, 2012, Science, 337:816), and the preference for an NGG/NRG motif immediately downstream of the protospacer restricts the ability to target on average every 12-bp in the human genome.
• a CRISPR complex comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins
• formation of a CRISPR complex results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
• the tracr sequence which may comprise or consist of al l or a portion of a wild- type tracr sequence (e.g.
• one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites.
• a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
• two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector.
• CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element.
• the coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction.
• a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron).
• the CRISPR enzyme, guide sequence, tracr mate seque ce, and tracr seque ce are operably linked to and expressed from the same promoter.
• a vector comprises one or more insertion sites, such as a restriction endo uclease recognition sequence (also referred to as a "cloning site").
• one or more insertion sites e.g. about or more than about L 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
• a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulator ⁇ ' element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expressio the guide sequence directs seque ce-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell
• a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site.
• the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these.
• a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
• a single vector may comprise about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-con taining vectors may be provided, and optionally delivered to a cell.
• a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein.
• Cas proteins include Casl, Cas IB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Cas 10, Csyl, Csy2, Csy3, Csel, Cse2, Csc!
• the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9.
• the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence, in some embodiments, a vector encodes a C ISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence.
• an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
• Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A in SpCas9.
• corresponding posticus may be conserved in other Cas9s, i.e. in Cas9 orthologs from or derived from other bacterial species, with reference to the position numbering of SpCas9.
• FIG. 19 shows a multiple sequence alignment of 12 Cas9 orthologs and indicates the conserved catalytic Asp residue in the RuvC I domain and the conserved catalytic His residue in the HNH domain. Mutation of one or the other residue into Ala may convert the Cas9 ortholog into a nickase. Mutation of both residues may convert the Cas9 ortholog into a catalytically null mutant - useful for generic DNA binding.
• two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III or the HNH domain) may be mutated to produce a mutated Cas9 ortholog substantially lacking ail DNA cleavage activity.
• a D10A mutation is combined with one or more of H840A, N854A, or N863 A mutations to produce a Cas9 enzyme substantially lacking ail DNA cleavage activity.
• a CRISPR enzyme is considered to substantially lack al l DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1%, 0.1 %.», 0.01%, or lower with respect to its non-mutated form.
• SpCas9 and SpCas9n indeed catalyzed integration of the HR template into the EMXl locus.
• PCR amplification of the target region followed by restriction digest with Hindlll revealed cleavage products corresponding to expected fragment sizes, with SpCas9 and SpCas9n mediating similar levels of HR efficiencies.
• Figure 10A-M provides a scheme indicating positions of mutations in SpCas9 and Cas9 orthologs typically share the general organization of 3-4 RuvC domains and a HNH domain. The 5' most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand.
• the catalytic residue in the 5' RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type 11 CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus), and the conserved Asp residue is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non ⁇ complenientary- strand nicking enzyme.
• an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells.
• the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human mammal including non-human primate.
• processes for modifying the germ line genetic identity of human beings and/or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes may be excluded.
• codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host ceils of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequent!)' or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
• codon bias differs in codon usage between organisms
• tRNA transfer RNA
• Codon usage tables are readily available, for example, at the "Codon Usage Database” available at www.kazusa.orjp/codon/ (visited Jul. 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000).
• codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available.
• one or more codons e.g. 1 , 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons
• one or more codons in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
• a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs.
• the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more N LSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus).
• the CRISPR enzyme comprises at most 6 NLSs.
• an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15. 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N ⁇ or C-terminus.
• Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence P KKRKV; the NLS from nudeoplasmin (e.g. the nucleopSasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK); the c-myc NLS having the amino acid sequence PAAKRVKLD or RQRRNELKRSP; the hRNPAl 9 NLS having the sequence ' NQSS ' NFGPM GGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence
• the sequence REKKKFLKRR of the mouse Mxl protein the sequence RKGDEVDGVDEVAKKKSKK of the human poIy(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK of the steroid hormone receptors (human) glucocorticoid.
• the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a delectable amount in the nucleus of a eukaryotic cell
• strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors.
• Detection of accumulation in the nucleus may be performed by any suitable technique.
• a detectable marker may be fused to the CRISPR enzyme, such that location withi a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI).
• Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expressio activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacki g the o e or more NLSs.
• an assay for the effect of CRISPR complex formation e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expressio activity affected by CRISPR complex formation and/or CRISPR enzyme activity
• a guide sequence is any polynucleotide sequence having sufficient com lementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
• the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm is about or more than about 50%. 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
• Optimal alignment may be determmed with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Need!eman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clusta!W, C!ustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocrafl.com), ELAND (Il lumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at matj.sourceforge.net).
• any suitable algorithm for aligning sequences include the Smith-Waterman algorithm, the Need!eman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clusta!W, C!ustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocrafl.
• a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay.
• the components of a CRISPR system sufficient to form a CRISPR complex may be provided to a host cell having the corresponding target sequence, such as by transfection wit -vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein.
• cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
• Cas9 nickases may be advantageously used in combination with pairs of guide RNAs to generate DNA double strand breaks with defined overhangs.
• pairs of guide RNAs When two pairs of guide RNAs are used, it is possible to excise an intervening DNA fragment. If an exogenous piece of DNA is cleaved by the two pairs of guide RNAs to generate compatible overhangs with the genomic DNA, then the exogenous DNA fragment may be ligated into the genomic DNA to replace the excised fragment. For example, this may be used to remove trinucleotide repeat expansion in the huntingtin (HTT) gene to treat Huntington's Disease.
• HTT huntingtin
• Cas9 and its chimeric guide RNA, or combination of tracrRNA and crRNA can be delivered either as DNA or RNA.
• Deliver)? of Cas9 and guide RN A both as RNA (normal or containing base or backbone modifications) molecules can be used to reduce the amount of time that Cas9 protein persist in the cell. This .may reduce the level of off-target cleavage activity in the target ceil. Since delivery of Cas9 as mRN A takes time to be translated into protein, it might be advantageous to deliver the guide RNA several hours following the delivery of Cas9 mRNA, to maximize the level of guide RNA available for interaction with Cas9 protein.
• a variety of delivery systems can be introduced to introduce Cas9 (DNA or RNA) and guide RNA (DNA or RNA) into the host cell. These include the use of liposomes, viral vectors, eleetroporation, nanoparticles , nanowires (Shaiek et aL Nano Letters, 2012), exosomcs. Molecular trojan horses liposomes (Pardridge et aL Cold Spring Harb Protoc; 2010; doi: 10.1101/pdb.prot5407) may be used to deliver Cas9 and guide RNA across the blood brain barrier.
• a guide sequence is selected to reduce the degree secondary structure within the guide RNA.
• Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133- 148).
• a method of optimizing the guide R.NA. of a Cas9 ortholog comprises breaking up polyU tracts in the guide RNA.
• PolyU tracts that may be broken up may comprise a series of 4, 5, 6, 7, 8, 9 or 10 Us.
• a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a eel i containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence.
• degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences.
• Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence.
• the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.
• the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length.
• the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin.
• the transcript or transcribed polynucleotide sequence has at least two or more hairpins.
• the transcript has two, three, four or five hairpins.
• the transcript has at most five hairpins. In a hairpin structure the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence.
• single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1) catgccgaaatcaacaccctgtcattttatggcagggtgttttcgttttaaTTTTTT; (2) NNNNNNNNN ⁇
• sequences (1) to (3) are used in combination with Cas9 from S. thermoph ius CR ISPRI .
• sequences (4) to (6) are used in combination with Cas9 from S. pyogenes.
• the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence.
• a recombination template is also provided.
• a recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide.
• a recombmation template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a part of a CRISPR complex.
• a template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length.
• the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence.
• a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1 , 5, 10, 15, 20, or more nucleotides).
• the nearest nucleotide of the template polynucleotide is within about 1 , 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
• the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme).
• a CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
• epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
• reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-giucuronidase, iuciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
• GST glutathione-S-transferase
• HRP horseradish peroxidase
• CAT chloramphenicol acetyltransferase
• beta-galactosidase beta-galactosidase
• beta-giucuronidase beta-galactosidase
• iuciferase green fluorescent protein
• GFP green fluorescent protein
• HcRed HcRed
• DsRed cyan fluorescent protein
• a CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP 16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US20110059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.
• MBP maltose binding protein
• DBD Lex A DNA binding domain
• HSV herpes simplex virus
• a CRISPR enzyme may form a component of an inducible system.
• the inducible nature of the system would al low for spatiotemporal control of gene editing or gene expression using a form of energy.
• the form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy.
• inducible system include tetracycline inducible promoters (Tet-On or Tct-Off , small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytochrome, LOV domains, or cryptochorome).
• the CRISPR enzyme may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner.
• the components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
• LITE Light Inducible Transcriptional Effector
• the components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
• the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell.
• the invention further provides cells produced by such methods, and animals comprising or produced from such cells.
• a CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to a ceil.
• Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism.
• Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
• RNA e.g. a transcript of a vector described herein
• Viral vector deli ver - systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
• Non-viral delivery of nucleic acids include lipofection, microinjection, biolistics, virosomes, liposomes, irnmunoliposom.es, poiycation or lipid :nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
• Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM).
• Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or e vivo administration) or target tissues (e.g. in vivo administration).
• lipid:nucleic acid complexes including targeted liposomes such as immunolipid complexes
• Boese et ai. Cancer Gene Ther, 2:291-297 (1995); Behr et aL Bioconjugate Chem. 5:382-389 (1994); Remy et ai, Bioconjugate Chem. 5:647-654 (1994); Gao et al, Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res, 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,2 17,344, 4,235,871, 4,261,975, 4,485,054, 4,501 ,728, 4,774,085, 4,837,028, and 4,946,787).
• RNA or DNA viral based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a vims to specific ceils in the body and trafficking the viral payload to the nucleus.
• Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo).
• Conventional viral based systems could include retroviral, lenti virus, adenoviral, adeno-associated and herpes simplex vims vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated vims gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different ceil types and target tissues.
• Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing ceils and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target ceil to provide permanent transgene expression.
• Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency vims (SIV), human immuno deficiency vims (HIV), and combinations thereof (see, e.g., Buchscher et al, J. Virol. 66:2731 -2739 (1992); Johami et al., J. Virol. 66: 1635-1640 (1992); Sommnerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al, J. Virol. 65:2220-2224 (1991); PCT/US94/Q57Q0).
• MiLV murine leukemia virus
• GaLV gibbon ape leukemia virus
• SIV Simian Immuno deficiency vims
• HV human immuno deficiency vi
• Adenoviral based systems may be used.
• Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system.
• Adeno-associated vims (“AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987): U.S. Pat. No.
• Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ⁇ 2 cells or PA317 cells, which package retrovirus.
• Viral vectors used in gene therapy are usually generated by producer a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the poiynucieotide(s) to be expressed . The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess I TR sequences from the AAV genome which are required for packaging and integration into the host genome.
• Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
• the cell line may also infected with adenovirus as a helper.
• the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
• the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817, incorporated herein by reference.
• AAV is considered an ideal candidate for use as a transducing vector.
• Such AA transducing vectors can comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpesvirus or poxvirus (e.g., vaccinia vims) helper functions provided in trans.
• Recombinant AAV rAAV
• rAAV Recombinant AAV
• the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice.
• Current AAV vectors may accommodate up to 4300 bases of inserted D NA.
• rAAV there are a number of ways to produce rAAV, and the invention provides rAAV and methods for preparing rAAV.
• piasmid(s) containing or consisting essential ly of the desired viral construct are transfected into AAV-infected cells.
• a second or additional helper plasmid is cotransfected into these cells to provide the AAV rep and/or cap genes which are obligatory for replication and packaging of the recombinant viral construct. Under these conditions, the rep and/or cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct.
• Two to Three days after transfection rAAV is harvested. Traditionally rAAV is harvested from the cells along with adenovirus.
• rAAV is advantageously harvested not from the cells themselves, but from cell supernatant.
• the invention provides for preparing rAAV, and in addition to the foregoing, rAAV can be prepared by a method that comprises or consists essentially of: infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, and helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia virus) wherein the rAAV lacks functioning cap and/or rep (and the helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia virus) provides the cap and/or rev function that the rAAV lacks); or infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, wherein the recombinant lacks functioning cap and
• helper vims e.g., adenovirus, herpesvirus, poxvirus such
• the rAAV can be from an AAV as herein described, and advantageousl can be an rAAVl, rAAV2, AAV5 or rAAV having hybrid or capsid which may comprise AAV1, AAV2, AAV5 or any combination thereof.
• AAV of the rAAV with regard to the cells to be targeted by the rAAV; e.g., one can select AAV serotypes 1, 2, 5 or a hybrid or capsid AAV 1, AAV2, AAV5 or any combination thereof for targeting brain or neuronal cells; and one can select AAV4 for targeting cardiac tissue, AAV8 for targeting of liver tissue.
• the invention provides rAAV that contains or consists essentially of an exogenous nucleic acid molecule encoding a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, e.g., a plurality of cassettes comprising or consisting a first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a CRISPR-assoeiated (Cas) protein (putative nuclease or helicase proteins), e.g., Cas9 and a terminator, and a two, or more, advantageously up to the packaging size limit of the vector, e.g., in total (including the first cassette) five, cassettes comprising or consisting essentially of a promoter, nucleic acid molecule encoding guide RNA (gRNA) and a terminator (e.g., each cassette schematically represented as Promoter-gRNAl -terminator, Promoter-gRNA2 -terminator
• Promoter- gRNA(N)-terminator (where is a number that can be inserted that is at an upper limit of the packaging size limit of the vector), or two or more individual rAAVs, each containing one or more than one cassette of a CRISPR.
• the promoter is in some embodiments advantageously human Synapsin I promoter (hSyn).
• Promoter-gRNA(N)-terminator up to size limit of vector
• Double virus vector Double virus vector
• Vector 1 containing one expression cassette for driving the expression of Cas9
• Vector 2 containing one more expression cassettes for driving the expression of one or more guideRNAs
• Promoter used to drive Cas9 coding nucleic acid molecule expression can include: AAV ITR can serve as a promoter: this is advantageous for eliminating the need for an additional promoter element (which can take up space in the vector). The additional space freed up can be used to drive the expression of additional elements (gRNA, etc). Also, ITR activity is relatively weaker, so can be used to reduce toxicity due to over expression of Cas9. [00182] For ubiquitous expression, can use promoters: CMV, CAG, CBh, PG , SV40, Ferritin heavy or light chains, etc.
• promoters For brain expression, can use promoters: Synapslnl for ail neurons, CaMKlIalpiia for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons, etc.
• ICAM ICAM
• hematopoietic cells can use IFNbeta or CD45
• Promoter used to drive guide RNA can include:
• Pol III promoters such as U6 or H 1
• the AAV can be AAV1, AAV2, AAV5 or any combination thereof.
• AAV8 is useful for delivery to the liver. The above promoters and vectors are preferred individually.
• a host cel l is transientl or non -transiently transfected with one or more vectors described herein.
• a cell is transfected as it naturally occurs in a subject.
• a cell that is transfected is taken from a subject.
• the cell is derived from cells taken from a subject, such as a cell line.
• a wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C816L CCRF-CEM, MOLT, mI CD-3, NHDF, HeLa-S3, Huh l, Huh4, Huh7, HUVEC, HASMC, i U .Kn.
• MCF-IOA MDA-MB-23 1 , MDA-MB-468, MDA-MB- 435, MDCK II, MDCK ]]]
• MOR/0.2R MONO-MAC 6
• MTD-1 A MyEnd
• NCI-H69/CPR NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, ⁇ H i - 3T3.
• Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Col lection (ATCC) (Manassus, Va.)).
• ATCC American Type Culture Col lection
• a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences.
• a ceil transiently transfected with the components of a CRISP R system as described herein (such as by transient iransfection of one or more vectors, or iransfection with RNA), and modified through the activity of a CRISPR complex, is used to establish a new ceil line comprising cells containing the modification but lacking any other exogenous sequence.
• cells transiently or non-tra siently transfected with one or more vectors described herein, or ceil lines derived from such cells are used in assessing one or more test compounds.
• one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant.
• the transgenic animal is a mammal, such as a mouse, rat, or rabbit.
• Methods for producing transgenic plants and animals are known in the art, and generally begin with a method of cell iransfection, such as described herein,
• the invention provides for methods of modifying a target polynucleotide in a eukaryotie cell, which may be in vivo, e vivo or in vitro.
• the method comprises sampling a cell or population of cells from a human or non- human animal or plant (including micro-algae), and modifying the cell or cel ls. Culturing may occur at any stage ex vivo.
• the cell or cells may even be re -introduced into the non-human animal or plant (including micro-algae). For re-introduced cells it is particularly preferred that the cells are stem cells.
• the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
• the invention provides a method of modifying expression of a polynucleotide in a eukaryotie cell.
• the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherem the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. Similar considerations apply as above for methods of modifying a target polynucleotide.
• kits containing any one or more of the elements disclosed in the above methods and compositions Elements may provide individually or in combinations, and may provided in any suitable container, such as a vial, a bottle, or a tube.
• the kit includes instructions in one or more languages, for example in more than one language.
• a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein.
• Reagents may be provided in any suitable container.
• a kit may provide one or more reaction or storage buffers.
• Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyophilize form).
• a buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof.
• the buffer is alkaline.
• the buffer has a pH from about 7 to about 10.
• the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element.
• the kit comprises a homologous recombination template polynucleotide.
• the invention provides methods for using one or more elements of a CRISPR system.
• the CRISPR complex of the invention provides an effective means for modifying a target polynucleotide.
• the CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types.
• the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis.
• An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide.
• the guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
• this invention provides a method of cleaving a target polynucleotide.
• the method comprises modifying a target polynucleotide using a CRISPR complex that binds to the target polynucleotide and effect cleavage of said target polynucleotide.
• the CRISPR complex of the invention when introduced into a cell, creates a break (e.g., a single or a double strand break) in the genome sequence.
• the method can be used to cleave a disease gene in a cell.
• the break created by the CRISPR complex can be repaired by a repair processes such as the error prone non-homologous end joining (NHEJ) pathway or the high fidelity homology- directed repair (HDR), During these repair processes, an exogenous polynucleotide template can be introduced into the genome sequence, hi some methods, the HDR process is used to modify a genome sequence.
• NHEJ error prone non-homologous end joining
• HDR homology- directed repair
• an exogenous polynucleotide template can be introduced into the genome sequence, hi some methods, the HDR process is used to modify a genome sequence.
• an exogenous polynucleotide template comprising a sequence to be integrated flanked by an upstream sequence and a downstream sequence is introduced into a ceil.
• the upstream and downstream sequences share sequence similarity with either side of the site of integration in the chromosome.
• a donor polynucleotide can be DNA, e.g., a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a PGR. fragment, a naked nucleic acid, or a nucleic acid complexed with a deliver ⁇ ' vehicle such as a liposome or poloxamer.
• DNA e.g., a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a PGR. fragment, a naked nucleic acid, or a nucleic acid complexed with a deliver ⁇ ' vehicle such as a liposome or poloxamer.
• the exogenous polynucleotide template comprises a sequence to be integrated (e.g, a mutated gene).
• the sequence for integration may be a sequence endogenous or exogenous to the cell.
• Examples of a sequence to be integrated include polynucleotides encoding a protein or a non-coding RNA (e.g., a microRNA).
• the sequence for integration may be operably linked to an appropriate control sequence or sequences.
• the sequence to be integrated may provide a regulatory function.
• the upstream and downstream sequences in the exogenous polynucleotide template are selected to promote recombination between the chromosomal sequence of interest and the donor polynucleotide.
• the upstream sequence is a nucleic acid sequence that shares sequence similarity with the genome sequence upstream of the targeted site for integration.
• the downstream sequence is a nucleic acid sequence that shares sequence similarity with the chromosomal sequence downstream of the targeted site of integration.
• the upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the targeted genome sequence.
• the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the targeted genome sequence. In some meihods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the targeted genome sequence.
• An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp.
• the exemplary upstream or downstream sequence has about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000 bp.
• the exogenous polynucleotide template may further comprise a marker.
• a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers.
• the exogenous polynucleotide template of the invention can be constructed using recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubei et al, 1996).
• a double stranded break is introduced into the genome sequence by the CRISPR complex, the break is repaired via homologous recombination an exogenous polynucleotide template such that the template is integrated into the genome.
• the presence of a double-stranded break facilitates integration of the templ ate.
• this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell.
• the method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide.
• a target polynucleotide can be inactivated to effect the modification of the expression in a cel l.
• the target polynucleotide upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does.
• a protein or microRNA coding sequence may be inactivated such that the protein is not produced.
• control sequence inactivated such that, it no longer functions as a control sequence.
• control sequence refers to any nucleic acid sequence that effects the transcription, translation, or accessibility of a nucleic acid sequence. Examples of a control sequence include, a promoter, a transcription terminator, and an enhancer are control sequences.
• the inactivated target sequence may include a deletion mutation (i.e., deletion of one or more nucleotides), an insertion mutation (i.e., insertion of one or more nucleotides), or a nonsense mutation (i.e., substitution of a single nucleotide for another nucleotide such that a stop codon is introduced).
• the hi activation of a target sequence results in "knockout" of the target sequence.
• An altered expression of one or more genome sequences associated with a signaling biochemical pathway can be determined by assaying for a difference in the mRNA levels of the corresponding genes between the test model cell and a control cell, when they are contacted with a candidate agent.
• the differential expression of the sequences associated with a signaling biochemical pathway is determined by detecting a difference in the level of the encoded polypeptide or gene product,
• nucleic acid contained in a sample is first extracted according to standard methods in the art.
• mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook et al. (1989), or extracted by nuclei c-acid-binding resins following the accompanying instructions provided by the manufacturers.
• the mRNA contained in the extracted nucleic acid sample is then detected by amplification procedures or conventional hybridization assays (e.g. Northern blot analysis) according to methods widely known in the art or based on the methods exemplified herein.
• amplification means any method employing a primer and a polymerase capable of replicating a target sequence with reasonable fidelity.
• Amplification may be carried out by natural or recombinant DNA polymerases such as TaqGoldTM, T7 DNA polymerase, Klenow fragment of E.coli DNA polymerase, and reverse transcriptase.
• a preferred amplification method is PGR.
• the isolated RN A can be subjected to a reverse transcription assay that is coupled with a quantitative polymerase chain reaction (RT-PCR) in order to quantify the expression level of a sequence associated with a signaling biochemical pathway.
• RT-PCR quantitative polymerase chain reaction
• Detection of the gene expression level can be conducted in real time in an amplification assay.
• the amplified products can be directly visualized with fluorescent DNA-binding agents including but not limited to DNA intercalators and DNA groove binders.
• DNA-binding dye suitable for this application include SYB green, SYBR blue, DAP], propidium iodine, Hoeste, SYBR gold, ethidium bromide, acridines, proflavine, acridine orange, aeriflaviiie, fluorcoumanin, eilipticiiie, daunomycin, ehloroquine, distamycin D, chromomycin, honiidium, mithramycin, ruthenium polypyridyis, anthramycin, and the like.
• probe-based quantitative amplification relies on the sequence-specific detection of a desired amplified product. It utilizes fluorescent, target-specific probes (e.g., TaqMan® probes) resulting in increased specificity and sensitivity. Methods for performing probe-based quantitative amplification are wel l established in the art and are taught in U.S. Patent No. 5,210,015.
• probes are allowed to form stable complexes with the sequences associated with a signaling biochemical pathway contained within the biological sample derived from the test subject in a hybridization reaction.
• antisense used as the probe nucleic acid
• the target polynucleotides provided in the sample are chosen to be complementary to sequences of the antisense nucleic acids.
• the target polynucleotide is selected to be complementary to sequences of the sense nucleic acid.
• Hybridization can be performed under conditions of various stringency, for instance as described herein. Suitable hybridization conditions for the practice of the present invention are such that the recognition interaction between the probe and sequences associated with a signaling biochemical pathway is both sufficiently specific and sufficiently stable. Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, for example, (Sambrook, et ah, (1989); Nonradioactive In Situ Hybridization Application Manual, Boehringer Mannheim, second edition).
• the hybridization assay can be formed using probes immobilized on any solid support, including but are not limited to nitrocellulose, glass, silicon, and a variety of gene arrays. A. preferred hybridization assay is conducted on high-density gene chips as described in U.S. Patent No. 5,445,934.
• the nucleotide probes are conjugated to a detectable label.
• Detectable labels suitable for use in the present invention include any composition detectable by photochemical, biochemical, spectroscopic, immunochemical, electrical, optical or chemical means.
• a wide variety of appropriate detectable labels are known in the art, which include fluorescent or chemiiuminescent labels, radioactive isotope labels, enzymatic or other ligands.
• fluorescent label or an enzyme tag such as digoxigenin, B-galactosidase, urease, alkaline phosphatase or peroxidase, avidin/biotin complex.
• the detection methods used to detect or quantify the hybridization intensity will typically depend upon the label selected above. For example, radiolabeis may be detected using photographic film or a phosphoimager. Fluorescent markers may be detected and quantified using a photodetector to detect emitted light. Enzymatic labels are typically detected by providing the enzyme with a substrate and measuring the reaction product produced by the actio of the enzyme on the substrate; and finally colorimetric labels are detected by simply visualizing the colored label.
• An agent-induced change in expression of sequences associated with a signaling biochemical pathway can also be determined by examining the corresponding gene products. Determining the protein level typically involves a) contacting the protein contained in a biological sample with an agent that specifically bind to a protein associated with a signaling biochemical pathway; and (b) identifying any agen protein complex so formed.
• the agent that specifically binds a protein associated with a signaling biochemical pathway is an antibody, preferably a monoclonal antibody.
• the reaction is performed by contacting the agent with a sample of the proteins associated with a signaling biochemical pathway derived from the test samples under conditions that will allow a complex to form between the agent and the proteins associated with a signaling biochemical pathway.
• the formation of the complex can be detected directly or indirectly according to standard procedures in the art.
• the agents are supplied with a detectable label and unreacted agents may be removed from the complex; the amount of remaining label thereby indicating the amount of complex formed.
• an indirect detection procedure may use an agent that contams a label introduced either chemically or enzymatical ly,
• a desirable label generally does not interfere with binding or the stability of the resulting agen polypeptide complex.
• the label is typically designed to be accessible to an antibody for an effective binding and hence generating a detectable signal.
• a wide variety of labels suitable for detecting protein levels are known in the art.
• Non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, biolumineseent compounds, and chermluminescent compounds.
• agent:polypeptide complexes formed during the binding reaction can be quantified by standard quantitative assays. As illustrated above, the formation of agentpolypeptide complex can be measured directly by the amount of label remained at the site of binding.
• the protein associated with a signaling biochemical pathway is tested for its ability to compete with a labeled analog for binding sites on the specific agent. In this competitive assay, the amount of label captured is inversely proportional to the amount of protein sequences associated with a signaling biochemical pathway present in a test sample.
• a number of techniques for protein analysis based on the general principles outlined above are available in the art. They include but are not limited to radioimmu oassays, ELISA (enzyme linked immunoradiometric assays), "sandwich” immunoassays, immunoradiometric assays, in situ immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays, and SDS-PAGE.
• radioimmu oassays ELISA (enzyme linked immunoradiometric assays), "sandwich” immunoassays, immunoradiometric assays, in situ immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays, and SDS-PAGE.
• Antibodies that specifically recognize or bind to proteins associated with a signaling biochemical pathway are preferable for conducting the aforementioned protein analyses.
• antibodies that recognize a specific type of post-transiationai modifications e.g., signaling biochemical pathway inducible modifications
• Post-translational modifications include but are not limited to giycosylation, lipidation, acetyi avion, and phosphorylation.
• These a tibodies may be purchased from commercial vendors.
• anti-phosphotyrosme antibodies that specifically recognize tyrosine-pbosphory!ated proteins are available from a number of vendors includi g Invitrogen and Perkin Elmer.
• Anti- phosphotyrosme antibodies are particularly useful in detecting proteins that are differentially phosphorylated on their tyrosine residues in response to an ER stress.
• proteins include but are not limited to eukaryotic translation initiation factor 2 alpha (eIF-2o).
• eIF-2o eukaryotic translation initiation factor 2 alpha
• these antibodies can be generated using conventional polyclonal or monoclonal antibody technologies by immunizing a host animal or an antibody-producing cell with a target protein that exhibits the desired post-translational modification.
• tissue-specific, cell-specific or subcellular structure specific antibodies capable of binding to protein markers that are preferentially expressed in certain tissues, cell types, or subcellular structures.
• An altered expression of a gene associated with a signaling biochemical pathway can also be determined by examining a change in activity of the gene product relative to a control cell.
• the assay for an agent-induced change in the activity of a protein associated with a signaling biochemical pathway will dependent on the biological activity and/or the signal transduction pathway that is under investigation. For example, where the protein is a kinase, a change in its ability to phosphorylate the downstream substrate(s) can be determined by a variety of assays known in the art.
• Representative assays include but are not limited to immuno blotting and immimoprecipitation with antibodies such as anti-phosphotyxosine antibodies that recognize phosphorylated proteins, hi addition, kinase activity can be detected by high throughput chemiluminescent assays such as AlphaScreenTM (available from Perkin Elmer) and eTagTM assay (Chan-Hui, et al. (2003) Clinical Immunology 111 : 162-174).
• AlphaScreenTM available from Perkin Elmer
• eTagTM assay Cho-Hui, et al. (2003) Clinical Immunology 111 : 162-174.
• pH sensitive molecules such as fluorescent pH dyes can be used as the reporter molecules.
• the protein associated with a signaling biochemical pathway is an ion channel
• fluctuations in membrane potential and/or intracellular ion concentration can be monitored.
• Representative instruments include FUP T (Molecular Devices, Inc.) and VIPR (Aurora Biosciences). These instruments are capable of detecting reactions in over 1000 sample wells of a microplate simultaneously, and providing real-time measurement and functional data within a second or even a minisecond.
• a suitable vector can be mtroduced to a ceil or an embryo via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporatioii, biolistics, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucieofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent-enhanced uptake of nucleic acids, and delivery via liposomes, immunoiiposomes, virosomes, or artificial virions.
• the vector is introduced into an embryo by microinjection.
• the vector or vectors may be microinjected into the nucleus or the cytoplasm of the embryo.
• the vector or vectors may be introduced into a ceil by nucieofection.
• the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic ceil.
• the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell.
• the target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).
• target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide.
• target polynucleotides include a disease associated gene or polynucleotide.
• a "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control.
• a disease-associated gene also refers to a gene possessing mutatio (s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
• the transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
• the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
• the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic ceil.
• the target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA),
• the target polynucleotide of a CRISPR complex may include a number of disease- associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides as listed in US provisional patent applications 61/736,527 and 61/748,427 having Broad reference BI-201 1/008/WSGR Docket No. 44063-701.10 land BI- 2011/008/WSGR Docket No. 44063-701.102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.
• target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide.
• target polynucleotides include a disease associated gene or polynucleotide.
• a "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control.
• a disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
• the transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
• SCIDXl SCIDX, IMD4
• HIV-l CCL5, SCYA5, D17S136E, TCP2248
• HI V susceptibility or infection IL10, CSIF, CMKBR2, CCR2,
• IL-17d ⁇ .- ⁇ .11-23, Cx3crl, ptpn22, ' I ' M ' a. NOD2/CARD15 for IBD, IL-6, 1L-12 (IL-12a, 1L-I2b), CTLA4, Cx3ci l); Severe combined immimodeficiencies (SCIDs)(JAK3. JAKL, DCLRE1C, ARTEMIS, SCIDA, RAG1, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D, T3D, 1L2RG, SCIDXl , SCIDX, IMD4).
• SCIDs Severe combined immimodeficiencies
• CF CF, MRP7; Glycogen storage diseases (SLC2A2, GLUT2, G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM); Hepatic adenoma, 142330 (TCFl, HNF1A, MODY3), Hepatic failure, early onset, and neurologic disorder (SCQD!, SCOl), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas (CTNNBl, PDGFR L, PDGRL, PRLTS, AXI 1, ⁇ , CTNNBl, TPS 3, P53, LFS1, IGF2R, MPRJ, MET, CASP8, Mi " !
• Glycogen storage diseases SLC2A2, GLUT2, G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS
• DMD Muscular / Skeletal Becker muscular dystrophy
• DMD Muscular / Skeletal Becker muscular dystrophy
• LMNA Emery-Dreifuss muscular dystrophy
• Neurological and ALS SODl, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a, VEGF-b, neuronal, diseases and VEGF-c); Alzheimer disease (APP, AAA, CVAP, ADl , APOE, AD2, disorders PSEN.2, AD4, STM2, APBB.2, FE65L1, NOS3, PLAU, URK, ACE,
• DCP l ACEL MPO, PACIP1, PAXIP1 L, PTIP, A2M, BLMH, BMH, PSEN1, AD3); Autism (Mecp2, BZRAP1, MDGA2, Sema5A, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX79, LGN3, NLGN4, ⁇ 1 ⁇ 1 260.
• VLDLR VLDLR
• Occular diseases and Age-related macular degeneration Abcr, Ccl2, Cc2, cp (ceruloplasmin), disorders Timp3, cathepsinD, Vidir, Ccr2); Cataract (CR.YAA, CR.YA 1, CRYBB2,
• Corneal clouding and dystrophy (APOA1, TGFBI, CSD2, CDGG 1 , CSD, BIGH3, CDG2, TACSTD2, TROP2, Ml SI, VSX i . RINX, PPCD, PPD, KTCN, COL8A2, FECD, PPCD2, PIP5K3, CFD); Cornea plana congenital (KERA, CNA2); Glaucoma (MYOC, TIGR, GLC1 A, JO AG, GPOA, OPTN, GLCI E, FIP2, HYPL, NRP, CYPIBL GLC3A, OPA ⁇ , NTG, NPG, CYPIBI, GLC3A); Leber congenital amaurosis (CRB1, RP12, CRX, CORD2, CRD, RPGRIP1 , LCA6, CORD9, RPE65, RP20,
• PIK3CA PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8;
• IGF1R insulin receptor
• IRS1 MAPK3
• IGFBP7 IGFBP7
• KRAS PIK3C2A
• PDPK1 MAP2K1; IGFBP2; SI N; JUN; CYR61; AKT3;
• NRF2 ⁇ mediated PRKCE EP300; SOD2; PRKCZ; MAPKl; SQSTM1;
• PRKD1 PRKD1; MAPK3; KRAS; PRKCD; GSTP1; MAPK9; FTL;
• MAP2K2 AKTl; PIK3R1 ; MAP2K1; PPIB; JUN; KEAP1;
• IGFIR insulin receptor RI
• IL6R RELA
• TLR4 PDGFRB
• TNF RELB
• IL8 IL8
• PDGFRA NFKBI
• TGFBR1 TGFBR1
• SMAD4 VEGFA
• BAX BAX
• IL1RI C( 1.2: HGF; MMP1; STAT1; IL6; CTGF; MMP9
• NRJP1 KRAS
• PPARG RELA
• STATS A TRAF2;
• MAP2K1 MAP2K1; NFKBI; JUN; IL1R1; HSP90AA1
• PRKD1 MAPK3; MAPK10; KRAS; MAPKl 3; PRKCD;
• MAPK9 PIK3C2A
• BTK PIK3C2A
• MAPK14 TNF
• RAFl FYN
• PIK3C3 MAPK3; KRAS; RELA; SRC; PIK3C2A; RAFl;
• PDPK1 PDPK1; STAT3; MAP2KI; NFKBI; BRAF; ATF4; AKT3;
• MAPKl Metabolism MAPKl; PLKl; AKT2; PIK3CA; CDK8; PIK3CB; PIK3C3;
• MAP2K1 MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
• EIF2AK2 ELKl
• ABL2 ABL2
• MAPKl PIK3CA
• FOS PIK3CB
• P1K3C3 P1K3C3; MAPK8; CAV ' l; ABL1; MAPK3; KRAS; SRC;
• PIK3C2A PIK3C2A
• PDGFRB PDGFRB
• RAFl RAFl
• MAP2K2 MAP2K2
• JAK1 JAK2
• JAK2 JAK2
• Trpal Pome; Cgrp; Of; Pica; Era; Nr2b; TRPM5; Prkaca;
• Prkacb Prka l a
• Prkar2a Prkacb
• IJMI Chordin (Chrd); Noggin (Nog); WNT (Wnt2;
• Wnt2b Wnt3a; Wnt4; Wnt5a; Wnt6; WntTb; Wnt8b;
• Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairing particular mutations associated with DNA repeat instability and neurological disorders (Robert. D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 2011 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeat instability: role of RNArDNA hybrids, Mclvor EI, Polak U, Napierala M. RNA Biol 2010 Sep-Oct;7(5):551-8). The CRISPR- Cas system may be harnessed to con'ect these defects of genomic instability,
• a further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease.
• Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence. A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently o therapy that has proven effective against disease progression.
• CRISP -Cas sytem Other genetic abnormalities associated with epilepsy may also be targeted by the CRISP -Cas sytem and the underlying genetics is further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzi i, Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology:20; 2009).
• the CRISPR-Cas system may be used to correct ocular defects thai arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.
• the genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barth Syndrome, Batten Disease, CAD ASH., Cerebellar Degeneration, Fabry's Disease, Gerstmann-Straussler-Scheinker Disease, Huntington's Disease and other Triplet Repeat Disorders, Leigh's Disease, Lesch-Nyhan Syndrome, Menkes Disease, Mitochondrial Myopathies and NINDS Colpocephafy. These diseases are further described on the website of the National Institutes of Health under the subsection Genetic Brain Disorders, [00238] in some embodiments, the condition may be neoplasia.
• the genes to be targeted are any of those listed in Table A (in this case PTEN asn so forth).
• the condition may be Age-related Macular Degeneration.
• the condition may be a Schizophrenic Disorder.
• the condition may be a Trinucleotide Repeat Disorder.
• the condition may be Fragile X Syndrome.
• the condition may be a Secretase Related Disorder.
• the condition may be a Prion - related disorder.
• the condition may be ALS.
• the condition may be a drug addiction.
• the conditio may be Autism.
• the condition may be Alzheimer's Disease.
• the condition may be inflammation.
• the condition may be Parkinson's Disease.
• proteins associated with Parkinson's disease include but are not limited to ot-symiciein, DJ-1, LRRK2, PINK 1. Parkin, UCHL1, Synphiiin-1, and NURR.l .
• Examples of addiction-related proteins may include ABAT for example,
• inflammation-related proteins may mclude the monocyte chemoattractant protein- 1 (MCP 1 ) encoded by the Ccr2 gene, the C-C chemokine receptor type 5
• CCR5 encoded by the Ccr5 gene
• FCGR2b also termed CD32
• FCERlg Fc epsilon R i g protein encoded by the Fcerlg gene
• cardiovascular diseases associated proteins may include (LIB (interleukin 1, beta), XDH (xanthine dehydrogenase), TPS 3 (tumor protein p53), PTGIS (prostaglandin 12 (prostacyclin) synthase), MB (myoglobin), 1L4 (interleukin 4), ANGPT! (angiopoietin 1), ABCG8 (ATP-binding cassette, sub-family G (WHITE), member 8), or CTSK (caihepsin K), for example.
• LIB internalleukin 1, beta
• XDH xanthine dehydrogenase
• TPS 3 tumor protein p53
• PTGIS prostaglandin 12 (prostacyclin) synthase)
• MB myoglobin
• 1L4 interleukin 4
• ANGPT! angiopoietin 1
• ABCG8 ATP-binding cassette, sub-family G (WHITE), member 8
• CTSK caihe
• Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin-like modifier activating enzyme 1 (UBA1) encoded by the UBA1 gene, or the NEDD8 -activating enzyme El catalytic subunit protein (UBE1C) encoded by the UBA3 gene, for example.
• VLDLR very low density lipoprotein receptor protein
• UBA1 ubiquitin-like modifier activating enzyme 1
• UBE1C El catalytic subunit protein
• proteins associated Autism Spectrum Disorder may include the benzodiazapine receptor (peripheral) associated protein 1 (BZRAP1) encoded by the BZRAP1 gene, the A F4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXRl ) encoded by the FXRl gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.
• BZRAP1 benzodiazapine receptor (peripheral) associated protein 1
• AFF2 family member 2 protein AFF2 family member 2 protein
• FXRl fragile X mental retardation autosomal homolog 1 protein
• FXR2 fragile X mental retardation autosomal homolog 2 protein
• proteins associated Macular Degeneration may include the ATP-binding cassette, sub-family A (ABCl.) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (C-C motif)
• Ligand 2 protein encoded by the CCL2 gene, for example.
• proteins associated Schizophrenia may include NRG1, ErbB4, CPLXl, TPH1, TPH2, NRXN1, GSK3A, BDNF, DISCI, GSK3B, and combinations thereof.
• proteins involved in tumor suppression may include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Notch2, Notch 3, or Notch 4, for example,
• proteins associated with a seeretase disorder may include PSENEN (presenilin enhancer 2 homolog (C. elegans)), CTSB (cathepsin B), PSEN l (preseniiin 1), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharynx defective 1 homolog B (C, elegans)), PSEN2 (presenilin 2 (Alzheimer disease 4)), or BACE1 (beta-site APP-cIeaving enzyme 1), for example.
• proteins associated with Amyotrophic Lateral Sclerosis may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
• proteins associated with prion diseases may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
• proteins related to neurodegenerative conditions in prion disorders may include A2M (Aipha-2-Macroglobulin), AATF (Apoptosis antagonizing transcription factor), ACPP (Acid phosphatase prostate), ACTA2 (Actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metallopeptidase domain), ADORA3 (Adenosine A3 receptor), or ADRA1D (Alpha- I D adrenergic receptor for Alpha- ID adrcnorcceptor), for example.
• A2M Alpha-2-Macroglobulin
• AATF Apoptosis antagonizing transcription factor
• ACPP Acid phosphatase prostate
• ACTA2 Actin alpha 2 smooth muscle aorta
• ADAM22 ADAM metallopeptidase domain
• ADORA3 Addenosine A3 receptor
• ADRA1D Alpha- I D adrenergic receptor for Alpha- ID adr
• proteins associated with Immunodeficiency may include A2M [alpha-2- macroglobulin]; A AN AT [arylalkylamine N-acetyltransferase]; ABCA 1 [ATP-binding cassette, sub-family A (ABO), member 1]; ABCA2 [ATP-binding cassette, sub-family A (ABC1), member 2]; or ABCA3 [ATP-binding cassette, sub-family A (ABC1 ), member 3]; for example.
• A2M alpha-2- macroglobulin
• a AN AT arylalkylamine N-acetyltransferase
• ABCA 1 ATP-binding cassette, sub-family A (ABO), member 1
• ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2]
• ABCA3 ATP-binding cassette, sub-family A (ABC1 ), member 3]; for example.
• proteins associated with Trinucleotide Repeat Disorders include AR (androgen receptor), FMR 1 (fragile X mental retardation 1), HTT (huntingtin), or DMP (dystrophia myotonic a-protein kinase), FXN (frataxin), ATXN2 (ataxiii 2), for example.
• proteins associated with Neurotransmission Disorders include SSI ' (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, alpha -2A-, receptor), ADRA2C (adrenergic, alpha-2C- s receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamine (serotonin) receptor 2C), for example.
• neurodeveiopmental-associated sequences include A2BP1 [ataxia 2- binding protein 1], AADAT [aminoadipate aminotransferase], AANAT [arylalkylamine N- acetyltransferase] , ABAT [4-aminobutyrate aminotransferase], ABCAl [ATP -binding cassette, sub-family A (ABCl), member 1], or ABCA l 3 [ATP-binding cassette, sub-family A (ABC1 ), member 13], for example.
• A2BP1 ataxia 2- binding protein 1
• AADAT aminoadipate aminotransferase
• AANAT arylalkylamine N- acetyltransferase
• ABAT 4-aminobutyrate aminotransferase
• ABCAl ATP -binding cassette, sub-family A (ABCl), member 1
• ABCA l 3 ATP-binding cassette, sub-family A (ABC
• FIG. 1 Aicardi-Goutieres Syndrome; Alexander Disease; Allan-Hemdon-Dudley Syndrome; POLG-Related Disorders; Alpha-Mannosidosis (Type I and II I); Alstrom Syndrome; Angelman; Syndrome; Ataxia-Telangiectasia; Neuronal Ceroid-Lipofuscinoses; Beta- Thalassemia; Bilateral Optic Atrophy and (Infantile) Optic Atrophy Type 1 ; Retinoblastoma (bilateral); Canavan Disease; Cerebrooculofacioskeietai Syndrome 1 [COFS l ]; Cerebrotendinous Xanthomatosis: Cornelia de Lange Svndrome; MAPT-Related Disorders; Genetic Prion Diseases; Dravet Syndrome; Early-Onset Familial Alzheimer Disease; Friedreich Ataxia [FRDA]; Fryns Syndrome; Fucosidosis; Fukuyama Congenital Mus
• Muscular Atrophy Infantile-Onset Spinocerebellar Ataxia; Hexosaminidase A Deficiency; Thanatophoric Dysplasia Type 1; Collagen Type VI-Related Disorders; Usher Syndrome Type I; Congenital Muscular Dystrophy; Wolf-Hirschhorn Syndrome; Lysosoma! Acid Lipase Deficiency; and Xeroderma Pigmentosum.
• the present system can be used to target any polynucleotide sequence of interest.
• Some examples of conditions or diseases that might be useful Sy treated using the present system are included in the Tables above and examples of genes currently associated with those conditions are also provided there. However, the genes exemplified are not exhaustive.
• Example 1 Improvement of the Cas9 system for in vivo application
• Most Cas9 orthoiogs are fairly !arge.
• Many known Cas9 ortho!ogs are large and contain more than 1300 amino acids.
• the SpCas9 is around 1368aa long, which is too large to be easily packaged into viral vectors for deliver)'.
• a graph representing the length distribution of Cas9 homologs is shown in Figure 6: The graph is generated from sequences deposited in GenBank. Some of the sequences may have been mis-annotated and therefore the exact frequency for each length may not necessarily be accurate. Nevertheless it provides a glimpse at distribution of Cas9 proteins and suggest that there are shorter Cas9 homologs.
• Campylobacter there are two Cas9 proteins with less than 1000 amino acids.
• the sequence for one Cas9 from Campylobacter jejuni is presented below.
• CjCas9 can be easily packaged into AAV, lentiviruses, Adenoviruses, and other viral vectors for robust delivery into primary cells and in vivo animal models.
• the Cas9 protein from 5. aureus is used.
• the putative tracrRNA element for this CjCas9 is:
• the wild-type CR ISPR-Cas system is an adaptive immune mechanism against invading exogenous DNA employed by diverse species across bacteria and archaea.
• the type 11 CRISPR-Cas system consists of a set of genes encoding proteins responsible for the "acquisition" of foreign DNA into the CRISPR locus, as well as a set of genes encoding the "execution" of the DNA. cleavage mechanism; these include the DNA nuclease (Cas9), a non- coding transactivating er-RNA (tracrRNA), and an array of foreign DNA-derived spacers flanked by direct repeats (crRNAs).
• the tracRNA and crRNA duplex guide the Cas9 nuclease to a target DNA sequence specified by the spacer guide sequences, and mediates double-stranded breaks in the DNA near a short sequence motif in the target DNA that is required for cleavage and specific to each CRISPR-Cas system.
• the type II CRISPR-Cas systems are found throughout the bacterial kingdom and highly diverse in Cas9 protein sequence and size, tracrRNA and crRNA direct repea sequence, genome organization of these elements, and the motif requirement for target cleavage.
• One species may have multiple distinct CRISPR- Cas systems,
• the tracr mate sequences or the direct repeats are either downloaded from the CRJSPRs database or identified in silico by searching for repetitive motifs that are 1. found in a 2kb window of genomic sequence flanking the type II CRISPR locus, 2. span from 20 to 50 bp, and 3. interspaced by 20 to 50 bp. In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used. In some embodiments candidate tracrRNA are subsequently predicted by 1. sequence homology to direct repeats (motif search in Geneious with up to 18-bp mismatches),
• chimeric synthetic guide R As (sgR As) designs incorporate at least 12 bp of duplex structure between the direct repeat and tracrRNA.
• tracrRNA candidate sequences Based on the direct repeat sequence, Applicants computationally searched for tracrRNA candidate sequences with the following criteria: outside the crRNA array but containing high degree of homology to direct repeats (as required for direct repea tracrRNA base-pairing; custom computational analysis), outside the coding regions of the protein components, containing Rho-independent transcriptional termination signals ⁇ 60bp-120bp downstream from region of homology from wit direct repeats, and co-folding with direct repeat to form a duplex, followed by two or more hairpin structures in the distal end of tracrRNA sequence. Based on these prediction criteria, Applicants selected an initial set of 18 Cas9 proteins and their uniquely associated direct repeats and traerRNAs distributed across all five Cas9 families.
• Applicants further generated a set of 18 chimeric RNA structures that preserved the sequence and secondary structures of the native direct repeat: tracrRNA duplex while shortening the region of base- pairing and fusing the two RNA. elements through an artificial loop ( Figures 8A-J).
• AAGGAGAACTAC ATG-AAGTGAATAGCA GTGCTACGAAGAGGCTAAAAAGCTGAAAAAG
• Applicants analyzed Cas9 orthologs to identify the relevant PAM sequences and the corresponding chimeric guide A as indicated in Figure 13A-II.
• This expanded set of PAM s provides broader targeting across the genome and also sig ificantly increases the number of unique target sites and provides potential for identifying novel Cas9s with increased levels of specificity in the genome.
• Applicants determined the PAM for Staphylococcus aureus subspecies Aureus Cas9 to be NNGRR ( Figure 14).
• Staphylococcus aureus subspecies Aureus Cas9 is also known as SaCas9.
• Figure 15 a-d provides SaCas9 single or multiple vector designs.
• Figure 7 show sequence logos for putative PAMs as indicated by reverse complements.
• Cas9 orthologs and their respective sgR As were used to cleave a library of targets bearing a randomized RAM (7-bp sequence immediately 3' of the target sequence). Cleaved products were isolated and deep-sequenced to yield 7-bp candidate sequences that were permissive to cleavage for each Ca.s9 orthofog.
• conse sus PAMs were determined by aligning all 7 -hp candidate sequences, ( Figures 7 and 21).
• Applicants show that the following mutations can convert SpCas9 into a nicking enzyme: D10A, E762A, 1 ⁇ 40 ⁇ . N854A, N863A, D986A.
• Applicants provide sequences showing where the mutation points are located within the SpCas9 gene (Figure 10A-M). Applicants also show that the niekases are still able to mediate homologous recombination. Furthermore, SpCas9 with these mutations (individually) reduce the level of double strand break. Cas9 orthologs all share the general organization of 3-4 RuvC domains and a HNH domain ( Figure 19). The 5' most RuvC domain cleaves the non- complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.
• the catalytic residue in the 5' RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type II CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type ( 1 CRISPR locus), and the conserved Asp residue is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non -complementary- strand nicking enzyme.
• Applicants For enhanced function or to develop new functions, Applicants generate chimeric Cas9 proteins by combining fragments from different Cas9 orthologs.
• chimeric Cas9 The benefit of making chimeric Cas9 include:
• AAV is advantagenous over other viral vectors for a couple of reasons:
• AAV vectors may accommodate up to 4300 bases of inserted DNA, as an upper limit or a packaging limit, AAV can have of 4.5 or 4,75 KB inserted DNA.
• DNA encoding a Cas9 enzyme as well as a promoter and transcription terminator have to be all fit into the same viral vector. Constructs larger than 4.5 or 4.75 KB will lead to significantly reduced vims production.
• SpCas9 is quite large, the gene itself is over 4.1kb, which makes it difficult for packing into AAV. Therefore embdiraents of the invention include utilizing orthologs of Cas9 that are shorter. For example:
• Figure 3 provides schematic representations of AAV vectors which may be used in methods and compositions of the invention. Packaging is discussed above.
• Method 1 Applicants deliver Cas9 and guide RNA using a vector that expresses Cas9 under the control of a constitutive promoter such as Hsp70A-R.bc S2 or Beta2 -tubulin.
• a constitutive promoter such as Hsp70A-R.bc S2 or Beta2 -tubulin.
• Method 2 Applicants deliver Cas9 and T7 polymerase using vectors that expresses Cas9 and T7 polymerase under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2 -tubulin.
• Guide RNA will be delivered using a vector containing T7 promoter driving the guide RNA.
• Method 3 Applicants deliver Cas9 mRNA and in vitro transcribed guide RNA to algae cells.
• RNA can be in vitro transcribed.
• Cas9 mRNA will consist of the coding region for Cas9 as well as 3'UTR from Co l to ensure stabilization of the Cas9 mRNA.
• Applicants generate a line of Chlamydomonas reinhardtii that expresses Cas9 eonstitutively. This can be done by using pCh!amy! (linearized using Pvui) and selecting for hygromycm resistant colonies. Sequence for pChiamyl containing Cas9 is below. In this way to achieve gene knockout one simply needs to deliver NA for the guideRNA. For homologous recombination Applicants deliver guideRNA as well as a linearized homologous recombination template.
• Example 8 SaCas9 and PAM recognition for in vivo applications
• Sp Streptococcus pyogenes
• St Streptococcus thermophiles
• CRISPR/Cas system with smaller size so Applicants could deliver them in vivo in a single vector with mammalian viral delivery system such as adeno-associated virus (AAV) vectors that has a packaging size limit (the current Sp or St system, exceed this limit of 4.7kb) [00303] and other desirable traits.
• mammalian viral delivery system such as adeno-associated virus (AAV) vectors that has a packaging size limit (the current Sp or St system, exceed this limit of 4.7kb) [00303] and other desirable traits.
• AAV adeno-associated virus
• Applicants designed a two- component system, where Applicants fused the Sa tracrRNA to the Sa guide CRJSPR RNA via a short stem-loop to form a chimeric guide RNA, exactly as Applicants did with the Streptococcus pyogenes (Sp) CRISPR/Cas system.
• This chimeric guide R A was able to support cleavage of dsDNA in vitro. Therefore, Applicants decided to clone the full two-component system: cas9 and the chimeric guide RNA, into an AAV vector to test its functionality in living organisms,
• Design of the initial AA V vector has (1) CMV promoter driving SaCas9 protein with a single NLS and a HA epitope tag. (2) human U6 promoter driving the chimeric RNA. These are placed in between two Inverted Terminal Repeats (iTRs) from the most-well studied AAV serotype 2 that serve as the viral packaging signal.
• iTRs Inverted Terminal Repeats
• the PAM sequence test on endogenous mammalian genome is as follows: SaCas9 target spacers were selected across multiple genes to cover different potential PAM sequences. Different spacers were cloned into U6-sgRNA (single-guide RNA) expression dsDNA cassette U6-sgRNA expression dsDNA cassette were co-transfected into mammalian cells lines (293FT for human targets, N2a and Hepa for mouse targets). 72 hours following trans fcction, all genomic DNA were extracted and subjected to surveyor nuclease assay. Run through TBE Page Gel to detect genomic cleavage. Quantify genomic DNA cleavage efficiency and plot.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Plant Pathology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Medicinal Chemistry (AREA)
• Virology (AREA)
• Cell Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Computational Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Veterinary Medicine (AREA)
• Mycology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Ophthalmology & Optometry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Enzymes And Modification Thereof (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (19)

Applications Claiming Priority (24)

Publications (2)

Family

ID=49883291

Family Applications (1)

Country Status (15)

Cited By (315)